During National Colorectal Cancers Consciousness Month.

Preventive Services Task Force guidelines demand regular screening of men and women for colorectal cancer, starting at age 50 years and continuing until age group 75 years, by any of the following three regimens: annual high-sensitivity fecal occult bloodstream testing; sigmoidoscopy every five years combined with high-sensitivity fecal occult bloodstream testing every three years; or screening colonoscopy at intervals of a decade.PRESS RELEASE SOUTH and DUBLIN SAN FRANCISCO, Calif., 6 July, 2015 /PRNewswire/ – – Allergan plc , a leading global pharmaceutical business, and Oculeve, a development-stage medical device business centered on developing novel treatments for dry eyesight disease, today announced that they have entered into an agreement under which Allergan shall acquire Oculeve in an all-cash transaction. Under the terms of the contract, Allergan will acquire Oculeve for a $125 million upfront payment and commercialization milestone obligations linked to Oculeve's lead advancement program OD-01. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program. Allergan's 2015 earnings-per-share forecast provided on May 11, 2015 is unchanged as a total consequence of the acquisition.